Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11
SAB Biotherapeutics Inc SABS
$3.60
▲ +0.84%
(+$0.03)
Open
$3.56
Prev Close
$3.57
Day Range
$3.52 – $3.65
52W Range
$1.60 – $6.60
Market Cap
$275.27M
P/E (TTM)
20.57
Beta
0.58
EPS (TTM)
$-1.42
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-01-12 |
| Shares Out. | 76,460,000 |
| Website | sab.bio/ ↗ |
| Phone | 13026365400 |
SAB Biotherapeutics Inc is a publicly traded company under the ticker symbol SABS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-05-01)
📰 Latest News for SABS
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
This QuickLogic Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11
Certain Restricted Stock Grants of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026.
Certain Stock Options of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026.
Certain Warrants of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026.
47,609,899 Common Stock of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026.